Category: Allogeneic Hemopoietic Stem Cell Transplant (alloHSCT)

Description

This page contains brief details about the drug treosulfan, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Treosulfan was approved by the FDA for medical use on 04/08/2015 as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Mechanism of Action of Treosulfan

Treosulfan is an alkylating agent. Its mechanism is to cause damage to the DNA structure, leading to inhibition of DNA replication and cancer cell death.

Uses of Treosulfan

Treosulfant is an anti-neoplastic medication belonging to the group called alkylating agents. This medicine is combined with Fludarabine to treat allogeneic hemopoietic stem cell transplant (alloHSCT) in adults with both malignant and non-malignant. In pediatric patients (older than one month), it treats malignant.

Treosulfan Dosage available

Treosulfan injection is administered as an intravenous infusion into the vein. If this injection is recommended for you, it will be given by a healthcare professional. Do not self-administer. Your physician will choose the dosage and administration frequency based on the medical condition because it differs for each person.